GZMB and neoplasm: The combination of SIRT with immune checkpoint inhibitors has demonstrated to enhance the systemic inflammatory response by reverting the suppressive phenotype derived by the upregulation of tumor induced immune checkpoints on peripheral and intratumoral immune cells and stimulating them to produce TNF α and granzyme B that lead to a sustained systemic inflammation and an increased anti-tumor response [13, 71, 72].